Investigating a new microRNA that helps regulate immune cells in autoimmune diseases
Official title: miR-342, a novel glucocorticoid-responsive miRNA necessary for Foxp3+ regulatory T cell function
Funded at Northwestern University at Chicago · NIH-10765692 · Data updated 2026-11-12
This study is looking at how a tiny molecule called miR-342 affects special immune cells that help keep our bodies balanced and prevent autoimmune diseases, and it’s exploring how common medications for inflammation might change this process to find better ways to treat these conditions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | January 18, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $240,000 |
| NIH project number | 5R21AI172135-02 |
| Project ID | NIH-10765692 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from autoimmune diseases who may benefit from improved immune regulation.
✕Less likely to help
Patients with non-autoimmune conditions or those not responding to glucocorticoid treatments may not benefit from this research.
What this research studies
This research focuses on understanding how a specific microRNA, known as miR-342, influences the function of regulatory T cells (Tregs), which are crucial for maintaining immune balance and preventing autoimmune diseases. The study examines how glucocorticoids, commonly used to treat inflammatory conditions, affect the expression of miR-342 in Tregs and how this microRNA regulates the metabolism and function of these immune cells. By exploring these mechanisms, the research aims to identify new therapeutic targets for improving treatments for autoimmune disorders.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for autoimmune diseases by enhancing the function of regulatory T cells.
How similar studies have gone: Previous research has shown that targeting microRNAs can successfully modulate immune responses, suggesting potential for success in this novel approach.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Min, Booki — Northwestern University at Chicago
- Study coordinator: Min, Booki
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.